Influenza Monthly Epidemiology Report, NSW

October 2018

This report describes the surveillance for influenza and other respiratory pathogens, undertaken by NSW Health to date. This includes data from a range of surveillance systems.


1. **Summary**

   - Influenza activity was low and decreasing throughout October. Influenza A was circulating at higher levels than influenza B.
   - The rate of influenza like illness (ILI) presentations to selected emergency departments was low and consistent with inter-seasonal activity.

2. **Hospital Surveillance**

   NSW emergency department (ED) surveillance for influenza-like illness (ILI) and other respiratory illnesses is conducted through PHREDSS [1].

   The PHREDSS surveillance system uses a statistic called the ‘index of increase’ to indicate when ILI presentations [2] are increasing at a statistically significant rate. It accumulates the difference between the previous day’s count of presentations and the average for that weekday over the previous 12 months. An index of increase value of 15 is considered an important indicator for the start of the influenza season in NSW as it suggests influenza is circulating widely in the community.

   In October 2018:

   - Presentations in the *All respiratory illness, fever and unspecified infections* category decreased and were slightly above the historical range for this time of year (Figure 1).
   - The index of increase for ILI presentations was 5.2 at the end October, well below the seasonal threshold of 15.
   - ED presentations for ILI increased but were steady and within the historical range for this time of year overall (Figure 2).
   - ED presentations for pneumonia [3] increased and were above the historical range for this time of year (Figure 3).
   - Pneumonia or ILI presentations which resulted in admissions to critical care units decreased and were within the historical range for this time of year (data not shown).

---

[1] NSW Health Public Health Rapid, Emergency Disease and Syndromic Surveillance system. Centre for Epidemiology and Evidence, NSW Ministry of Health. Comparisons are made with data for the proceeding five years. Recent counts are subject to change. As of 31 March 2016, data from 60 NSW emergency departments (EDs), representing approximately 82% of ED visits in the 2015-16 financial year. The coverage of rural EDs is lower than the metropolitan EDs. Data shown represents unplanned presentations to hospital EDs.

[2] The ED ‘ILI’ syndrome includes provisional diagnosis selected by a clinician of ‘influenza-like illness’ or ‘influenza’ (including pneumonia with influenza), avian and other new influenza viruses.

• Bronchiolitis presentations decreased and were within the usual range for this time of year, overall (Figure 4).

**Figure 1:** Total weekly counts of ED visits for any respiratory illness, fever and unspecified infections, all ages, 2018 (black line) to 28 October, compared with the 5 previous years (coloured lines).

**Figure 2:** Total weekly counts of ED visits for influenza-like illness, all ages, 2018 (black line) to 28 October, compared with the 5 previous years (coloured lines).

**Figure 3:** Total weekly counts of Emergency Department visits for pneumonia, 2018 (black line) to 28 October, compared with the 5 previous years (coloured lines).

**Figure 4:** Total weekly counts of Emergency Department visits for bronchiolitis, 2018 (black line) to 28 October, compared with the 5 previous years (coloured lines).
3. Laboratory testing summary for influenza

Sentinel laboratory surveillance for influenza and other respiratory viruses is conducted throughout the year [4]. In the four week period to October 28 2018:

- A total of 28,658 tests for respiratory viruses were performed at sentinel NSW laboratories (Table 1). The influenza percent positive rate was 5.0%, lower than the previous month (10.4%). Activity continued to decline throughout October and is now well below the seasonal threshold.
- 1257 specimens tested positive for influenza A – 40 of these tested positive for A(H3N2), 86 tested positive for influenza A(H1N1) and 1131 were not typed further (Table 1, Figures 5 & 6).
- 168 cases of influenza B were reported (Table 1, Figures 5 & 6).

Rhinovirus detections continued to increase and was the leading respiratory virus identified by laboratories.

**Table 1**: Summary of testing for influenza and other respiratory viruses at sentinel NSW laboratories, 1 January to 28 October 2018.

<table>
<thead>
<tr>
<th>Month ending</th>
<th>Total Tests</th>
<th>Influenza A</th>
<th>Influenza B</th>
<th>Adeno</th>
<th>Parainf 1, 2 &amp; 3</th>
<th>RSV</th>
<th>Rhino</th>
<th>HMPV</th>
<th>Entero</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total (%)</td>
<td>H3N2 (%)</td>
<td>H1N1 pdm09</td>
<td>A (Not typed)</td>
<td>Total (%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
</tr>
<tr>
<td>28/01/2018</td>
<td>12819</td>
<td>483 (3.8%)</td>
<td>26 (0.2%)</td>
<td>36 (0.3%)</td>
<td>414 (32.7%)</td>
<td>18 (0.1%)</td>
<td>507 (3.9%)</td>
<td>404 (3.1%)</td>
<td>492 (3.8%)</td>
</tr>
<tr>
<td>25/02/2018</td>
<td>14540</td>
<td>531 (3.7%)</td>
<td>46 (0.3%)</td>
<td>36 (0.2%)</td>
<td>447 (30.7%)</td>
<td>20 (0.1%)</td>
<td>503 (3.4%)</td>
<td>374 (2.6%)</td>
<td>546 (3.7%)</td>
</tr>
<tr>
<td>01/04/2018*</td>
<td>22518</td>
<td>524 (2.3%)</td>
<td>53 (0.2%)</td>
<td>52 (0.2%)</td>
<td>419 (18.7%)</td>
<td>42 (1.9%)</td>
<td>424 (1.9%)</td>
<td>703 (3.1%)</td>
<td>1057 (4.7%)</td>
</tr>
<tr>
<td>29/04/2018</td>
<td>19688</td>
<td>247 (1.2%)</td>
<td>22 (0.1%)</td>
<td>37 (0.2%)</td>
<td>188 (9.6%)</td>
<td>147 (0.7%)</td>
<td>147 (0.7%)</td>
<td>640 (3.3%)</td>
<td>869 (4.4%)</td>
</tr>
<tr>
<td>27/05/2018</td>
<td>24227</td>
<td>232 (1.0%)</td>
<td>21 (0.1%)</td>
<td>36 (0.2%)</td>
<td>175 (7.2%)</td>
<td>89 (0.4%)</td>
<td>89 (0.4%)</td>
<td>696 (3.0%)</td>
<td>843 (3.5%)</td>
</tr>
<tr>
<td>01/07/2018*</td>
<td>33785</td>
<td>402 (1.2%)</td>
<td>9 (0.0%)</td>
<td>43 (0.1%)</td>
<td>430 (12.9%)</td>
<td>72 (0.2%)</td>
<td>72 (0.2%)</td>
<td>1157 (34.7%)</td>
<td>971 (28.8%)</td>
</tr>
<tr>
<td>29/07/2018</td>
<td>31992</td>
<td>1126 (3.5%)</td>
<td>9 (0.0%)</td>
<td>156 (0.5%)</td>
<td>961 (30.5%)</td>
<td>83 (0.3%)</td>
<td>83 (0.3%)</td>
<td>1268 (40.6%)</td>
<td>913 (28.8%)</td>
</tr>
<tr>
<td>02/09/2018*</td>
<td>46926</td>
<td>3499 (7.5%)</td>
<td>60 (1.3%)</td>
<td>230 (0.5%)</td>
<td>3209 (91.7%)</td>
<td>473 (1.0%)</td>
<td>473 (1.0%)</td>
<td>1749 (37.3%)</td>
<td>1305 (28.3%)</td>
</tr>
<tr>
<td>30/09/2018*</td>
<td>39322</td>
<td>3729 (9.5%)</td>
<td>53 (1.4%)</td>
<td>223 (0.6%)</td>
<td>3458 (89.7%)</td>
<td>359 (0.9%)</td>
<td>359 (0.9%)</td>
<td>1590 (46.1%)</td>
<td>1540 (46.1%)</td>
</tr>
<tr>
<td>28/10/2018</td>
<td>28658</td>
<td>1257 (4.4%)</td>
<td>40 (1.4%)</td>
<td>86 (0.3%)</td>
<td>1131 (40.0%)</td>
<td>168 (0.6%)</td>
<td>168 (0.6%)</td>
<td>1303 (45.5%)</td>
<td>1367 (47.7%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Week ending</th>
<th>Total Tests</th>
<th>Influenza A</th>
<th>Influenza B</th>
<th>Adeno</th>
<th>Parainf 1, 2 &amp; 3</th>
<th>RSV</th>
<th>Rhino</th>
<th>HMPV</th>
<th>Entero</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/10/2018</td>
<td>7439</td>
<td>511 (6.9%)</td>
<td>8 (1.1%)</td>
<td>35 (0.5%)</td>
<td>468 (62.8%)</td>
<td>46 (0.7%)</td>
<td>353 (4.7%)</td>
<td>394 (5.3%)</td>
<td>230 (3.1%)</td>
</tr>
<tr>
<td>14/10/2018</td>
<td>7430</td>
<td>334 (4.5%)</td>
<td>10 (1.3%)</td>
<td>23 (0.3%)</td>
<td>301 (40.4%)</td>
<td>52 (0.7%)</td>
<td>354 (4.7%)</td>
<td>333 (4.5%)</td>
<td>219 (2.9%)</td>
</tr>
<tr>
<td>21/10/2018</td>
<td>7056</td>
<td>237 (3.4%)</td>
<td>8 (1.2%)</td>
<td>14 (0.2%)</td>
<td>215 (30.4%)</td>
<td>43 (0.6%)</td>
<td>316 (4.5%)</td>
<td>324 (4.6%)</td>
<td>184 (2.6%)</td>
</tr>
<tr>
<td>28/10/2018</td>
<td>6725</td>
<td>115 (1.7%)</td>
<td>14 (2.1%)</td>
<td>14 (0.2%)</td>
<td>147 (21.8%)</td>
<td>24 (0.3%)</td>
<td>280 (4.2%)</td>
<td>336 (4.9%)</td>
<td>174 (2.6%)</td>
</tr>
</tbody>
</table>

**Notes:**
* Five week period; ** HMPV - Human metapneumovirus.

All samples are tested for influenza viruses but not all samples are tested for all of the other viruses listed.

[4]: Preliminary laboratory data is provided by participating sentinel laboratories on a weekly basis and are subject to change. Point-of-care test results have been included since August 2012 but serological diagnoses are not included. Preliminary data are provided by participating sentinel laboratories on a weekly basis and are subject to change.

**Participating sentinel laboratories:** Pathology North (Hunter, Royal North Shore Hospital), Pathology West (Nepean, Westmead), South Eastern Area Laboratory Services, Sydney South West Pathology Service (Liverpool, Royal Prince Alfred Hospital), The Children’s Hospital at Westmead, Australian Clinical Labs, Douglas Hanly Moir Pathology, Laverty Pathology, Medlab, SydPath.
Figure 5: Weekly influenza positive test results by type and sub-type reported by NSW sentinel laboratories, 1 January to 28 October 2018.

Figure 6: Percent of laboratory tests positive for influenza A and influenza B reported by NSW sentinel laboratories, 1 January 2013 to 28 October 2018.
4. Community Surveillance

**Influenza notifications by Local Health District (LHD)**

In the four week period to October 28 2018 there were 1360 notifications of influenza confirmed by polymerase chain reaction (PCR) testing, lower than the 6569 influenza notifications reported for October 2017, and lower than the number of notifications reported for September 2018 (3972).

Influenza notification rates were low and stable across all NSW LHDs (Table 2).

**Table 2: Weekly notifications of laboratory-confirmed influenza by Local Health District.**

<table>
<thead>
<tr>
<th>Local Health District</th>
<th>Week ending 28 Oct 2018</th>
<th></th>
<th>Previous 4 weeks</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of notifications</td>
<td>Rate per 100 000 population</td>
<td>Number of notifications</td>
<td>Rate per 100 000 population</td>
</tr>
<tr>
<td>Central Coast</td>
<td>4</td>
<td>1.16</td>
<td>21</td>
<td>5.96</td>
</tr>
<tr>
<td>Far West</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>3.33</td>
</tr>
<tr>
<td>Hunter New England</td>
<td>19</td>
<td>2.04</td>
<td>60</td>
<td>6.38</td>
</tr>
<tr>
<td>Illawarra Shoalhaven</td>
<td>11</td>
<td>2.67</td>
<td>25</td>
<td>6</td>
</tr>
<tr>
<td>Mid North Coast</td>
<td>11</td>
<td>4.98</td>
<td>12</td>
<td>5.2</td>
</tr>
<tr>
<td>Murrumbidgee</td>
<td>1</td>
<td>0.41</td>
<td>14</td>
<td>5.57</td>
</tr>
<tr>
<td>Nepean Blue Mountains</td>
<td>7</td>
<td>1.85</td>
<td>24</td>
<td>6.39</td>
</tr>
<tr>
<td>Northern NSW</td>
<td>19</td>
<td>6.26</td>
<td>19</td>
<td>6.26</td>
</tr>
<tr>
<td>Northern Sydney</td>
<td>23</td>
<td>2.46</td>
<td>69</td>
<td>7.41</td>
</tr>
<tr>
<td>South Eastern Sydney</td>
<td>17</td>
<td>1.82</td>
<td>49</td>
<td>5.26</td>
</tr>
<tr>
<td>South Western Sydney</td>
<td>11</td>
<td>1.11</td>
<td>77</td>
<td>7.66</td>
</tr>
<tr>
<td>Southern NSW</td>
<td>3</td>
<td>1.42</td>
<td>3</td>
<td>1.42</td>
</tr>
<tr>
<td>Sydney</td>
<td>5</td>
<td>0.74</td>
<td>34</td>
<td>4.95</td>
</tr>
<tr>
<td>Western NSW</td>
<td>1</td>
<td>0.35</td>
<td>9</td>
<td>3.1</td>
</tr>
<tr>
<td>Western Sydney</td>
<td>22</td>
<td>2.2</td>
<td>81</td>
<td>8.07</td>
</tr>
</tbody>
</table>

**Note:** All data are preliminary and may change as more notifications are received. Excludes notifications based on serology.

**Influenza outbreaks in institutions**

There were 8 respiratory outbreaks in residential care facilities reported in October; three were caused by influenza A and three by influenza B, one outbreak was due to RSV and the cause of the other respiratory outbreak was unknown.

In the year to date there have been 39 laboratory confirmed influenza outbreaks in institutions reported to NSW public health units, including 36 in residential care facilities (Table 3, Figure 7). Of these 25 have been due to influenza A and 11 were due to influenza B.

In the 36 influenza outbreaks affecting residential care facilities, at least 335 residents were reported to have had ILI symptoms and 35 required hospitalisation. Overall, there have been nine deaths in residents reported which were linked to these outbreaks, all of whom were noted to have other significant co-morbidities.

**Table 3: Reported influenza outbreaks in NSW institutions, January 2011 to October 2018.**

<table>
<thead>
<tr>
<th>Year</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018*</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of outbreaks</td>
<td>4</td>
<td>39</td>
<td>12</td>
<td>120</td>
<td>103</td>
<td>279</td>
<td>588</td>
<td>39</td>
</tr>
</tbody>
</table>

**Notes:** * Year to date.
Figure 7: Reported influenza outbreaks in NSW residential care facilities by month, 2014 to 2018.

5. National and International Influenza Surveillance

National Influenza Surveillance

The most recent available information is in the Australian Surveillance Report No.11, with data up to 21 October 2018. Nationally, influenza activity declined this reporting fortnight after reaching a peak in early September. Surveillance systems indicate that national activity levels have returned to or are approaching baseline levels. Of note:

- **Severity** – Clinical severity for the season to date, as measured through the proportion of patients admitted directly to ICU, and deaths attributed to influenza, is moderate.
- **Impact** – Currently, the impact of circulating influenza on society, as measured through the proportion of people with ILL taking time off work, and the burden on hospitals, is low.
- **Virology** – In the last fortnight, the majority of confirmed influenza cases reported nationally were influenza A (83%), and where subtyping data were available, influenza A(H1N1)pdm09 was the dominant subtype.
- **At-risk populations:** Children aged less than 10 years appear to be more commonly infected with influenza; however the severity of illness in this population is on par with other age-groups.
- **Vaccine effectiveness:** Based on currently available data, vaccinated individuals were 68% less likely to present to a GP and 66% less likely to be hospitalised due to influenza, when compared to unvaccinated individuals.

Information provided by the WHO Collaborating Centre for Reference and Research on Influenza noted that of the 77 influenza B samples submitted from NSW for typing so far this year, only two were typed as in the B/Victoria lineage, with the remainder in the B/Yamagata lineage. Approximately two-thirds of the influenza A samples submitted from NSW have been the A(H1N1) strain.

For further information see the [Australian Influenza Surveillance Reports](https://www.aihrs.org.au).
Global Influenza Update
The latest WHO global update on 29 October 2018 provides data up to 14 October. In the temperate zone of the northern hemisphere influenza activity remained at inter-seasonal levels. Increased influenza detections were reported in some countries of Southern and South-East Asia. In the temperate zones of the southern hemisphere, influenza activity appeared to decrease overall. Worldwide, seasonal influenza subtype A viruses accounted for the majority of detections. Follow the link for the WHO influenza surveillance reports.

Influenza at the human-animal interface
WHO publishes regular updated risk assessments of human infections with avian and other non-seasonal influenza viruses at Influenza at the human-animal interface, with the most recent report published on 21 September 2018. These reports provide information on human cases of infection with non-seasonal influenza viruses, such as H5, H7, and H3N2 variant viruses, and outbreaks among animals.

Since the previous update, new human infections with avian influenza A(H5N6) and A(H9N2) viruses, and influenza A(H1N2) variant viruses were reported. The overall public health risk from currently known influenza viruses at the human-animal interface has not changed, and the likelihood of sustained human-to-human transmission of these viruses remains low. Further human infections with viruses of animal origin are expected.

Other sources of information on avian influenza and the risk of human infection include:

- US CDC Avian influenza
- European CDC (ECDC) Avian influenza
- Public Health Agency of Canada Avian influenza H7N9.

6. Composition of 2019 Australian influenza vaccines
The WHO Consultation on the Composition of Influenza Vaccines for the 2019 Southern Hemisphere was held in Atlanta on 24-26 September 2018.

Following the Consultation, WHO announced its recommendations for the composition of trivalent vaccines for use in the 2019 Southern Hemisphere influenza season, which includes changes in the influenza A(H3N2) component and the influenza B (Victoria lineage), as follows:

- an A/Michigan/45/2015 (H1N1)pdm09-like virus
- an A/Switzerland/8060/2017 (H3N2)-like virus
- a B/Colorado/06/2017-like virus (B/Victoria lineage)

It was recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a second B component as follows:

- a B/Phuket/3073/2013-like virus (B/Yamagata lineage).

More details about the most recent influenza vaccine recommendations can be found at: http://www.who.int/influenza/vaccines/virus/recommendations/2019_south/en/.

Information for immunisation providers on the influenza vaccines available for use in Australia in 2018, including vaccines used as part of the National Immunisation Program can be found at: https://beta.health.gov.au/resources/publications/atagi-advice-on-seasonal-influenza-vaccines-in-2018.
Information on NSW seasonal influenza vaccination activities in 2018, including free vaccine for all children aged 6 months to less than 5 years can be found at:

More details about the most recent influenza vaccine recommendations can be found at:

The WHO consultation on the composition of influenza vaccines for the Northern Hemisphere 2018-19 influenza season was held in February 2018. WHO announced its recommendations for the composition of quadrivalent vaccines for use in the 2018-19 Northern Hemisphere influenza season, which includes changes in the influenza A(H3N2) and influenza B (Victoria lineage) components, as follows:

- an A/Michigan/45/2015 (H1N1)pdm09-like virus\(^5\);
- an A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus;
- a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage)\(^6\); and
- a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).

\(^1\) This replaces A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus used in the 2018 seasonal influenza vaccines.

\(^2\) The B/Colorado/06/2017-like virus replaces the B/Brisbane/60/2008-like virus in the B/Victoria lineage. It is also now the preferred B strain component for 2019 Southern Hemisphere trivalent influenza vaccines, replacing the B/Yamagata lineage strain, B/Phuket. The B/Phuket strain remains the recommended B/Yamagata lineage strain for 2019 quadrivalent vaccines.

\(^5\) This replaces A/Hong Kong/4801/2014 (H3N2)-like virus used in the 2017-8 seasonal influenza vaccines.

\(^6\) This replaces B/Brisbane/60/2008-like virus used in the 2017-8 seasonal influenza vaccines. The B/Colorado will make up the B component of the trivalent vaccine.